Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
|ClinicalTrials.gov Identifier: NCT01771653|
Recruitment Status : Completed
First Posted : January 18, 2013
Last Update Posted : January 18, 2016
|Condition or disease|
|Hepatitis C Infection|
|Study Type :||Observational|
|Actual Enrollment :||37 participants|
|Official Title:||Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||July 2015|
Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin
Records of patients who have never received anti-HCV treatment.
- Virologic Response [ Time Frame: up to 96 weeks post treatment ]Sustained Virologic Response (SVR) rates will be compared between the two arms of treatment through measured HCV RNA levels after 24 weeks, 48 weeks and 96 weeks after completion of treatment.
- Adverse events [ Time Frame: 24, 48, and 96 weeks post treatment ]Comparison of rates and severity of adverse events between the two study arms
- Effect of baseline variables on treatment outcome [ Time Frame: 24, 48, and 96 weeks post treatment ]Analyze the effects of baseline variables on treatment outcome between the two groups- age, race, social economic status.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01771653
|United States, Illinois|
|Southern Illinois University School of Medicine|
|Springfield, Illinois, United States, 62701|
|Principal Investigator:||Janak Koirala, MD, MPH||Southern Illinois University School of Medicine|